1. Treatment for stroke
JPI-289 is a new synthetic molecule, which demonstrates outstanding benefits for stroke treatment. Jeil has completed phase I study, acquired IND approval, and is recruiting stroke patients for phase 2A clinical trial. JPI-289 showed excellent efficacy in a monkey stroke model.
2. Anti-cancer agent
JPI-547 is an anti-cancer agent and acts as a dual inhibitor of PARP and tankyrase. Non-clinical study of JPI-547 was completed and the IND for Phase 1 was approved. Phase Ia has been accomplished and phase 1b clinical trial is in progress.
3. SGLT1/2 dual inhibitor for type 1 diabetes treatment
JP-2266 is a new synthetic small molecule that controls postprandial hyperglucose by oral administration to improve conditions of type 1 diabetes mellitus and can be used as combination therapy with insulin. Pre-clinical studies of JP-2266 were completed and CTA filing for phase 1 clinical trial in Europe is in progress.
4. P-CAB (Potassium-Competitive Acid Blocker) for GERD
Jeil has developed a drug for GastroEsophageal Reflux Disease (GERD) treatment having unique mode of action compared to that of proton pump inhibitors (PPIs). Phase 1 studies were completed and Phase 2 trial is on-going in Korea.
5. Discovery Projects
Currently, research on various discovery projects including anti-cancer and anti-reumatoid arthritis is actively underway. At least two of the projects are expected to enter into pre-clinical stage within next two years.